Ortin Global

What does Ortin Global do?

Ortin Global Ltd is an Indian pharmaceutical manufacturer focused on drug formulations, classified as a micro-cap company with a market cap of Rs 9 Cr. As of March 2025, it reported net sales and net profit of 0 Cr.

Overview:<BR>Ortin Global Ltd is a leading pharmaceutical manufacturer in India, specializing in the production of various drug formulations within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>History:<BR>Ortin Laboratories Limited was incorporated in October 1986. The latest quarterly results reported net sales and net profit of 0 Cr for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 9 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.11 <BR>Return on Equity: -38.22% <BR>Price to Book: 4.21<BR><BR>Contact Details:<BR>Address: D No 1-8-B4 Ground Floor F3, HIG Block-4 Street No 3 Hyderabad Telangana : 500044 <BR>Email: info@ortinlabsindia.com <BR>Website: http://www.ortinlabsindia.com

Who are in the management team of Ortin Global?

As of March 2022, the management team of Ortin Global includes S Murali Krishna Murthy (Managing Director), S Srinivas Kumar (Whole Time Director & CFO), J R K Panduranga Rao (Chairman & Independent Director), and several other directors and independent directors. They are responsible for the company's governance and management.

As of March 2022, the management team of Ortin Global includes the following individuals:<BR><BR>1. S Murali Krishna Murthy - Managing Director<BR>2. S Balaji Venkateswarlu - Director<BR>3. S Srinivas Kumar - Whole Time Director & CFO<BR>4. J R K Panduranga Rao - Chairman & Independent Director<BR>5. Gaddam Venkata Ramana - Director<BR>6. Bhupathiraju S Raju - Director<BR>7. B Gopal Reddy - Independent Director<BR>8. Murali Krishna Rayaprolu - Independent Director<BR>9. Pottur Sujatha - Independent Director<BR>10. Harish Sharma - Company Secretary / Compliance<BR><BR>These individuals play key roles in the governance and management of the company.

Has Ortin Global declared dividend?

Ortin Global Ltd has declared a 2% dividend, but the dividend yield is 0%. The company has experienced significant price declines over various periods, resulting in negative total returns.

Ortin Global Ltd has declared a 2% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 2%<BR>- Ex-date: 24 Sep 13<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -42.2%, with a dividend return of 0%, resulting in a total return of -42.2%.<BR><BR>In the 1-year period, the price return was -37.88%, with a dividend return of 0%, leading to a total return of -37.88%.<BR><BR>Over the 2-year period, the price return was -41.24%, and the dividend return was 0%, culminating in a total return of -41.24%.<BR><BR>In the 3-year period, the price return was -54.25%, with a dividend return of 0%, resulting in a total return of -54.25%.<BR><BR>For the 4-year period, the price return was -59.5%, with a dividend return of 0%, leading to a total return of -59.5%.<BR><BR>In the 5-year period, the price return was -8.13%, and the dividend return was 0%, resulting in a total return of -8.13%.<BR><BR>Overall, Ortin Global has declared a dividend, but the dividend yield is 0%. The total returns over various periods indicate significant declines in price, suggesting challenges in the company's performance.

Who are the peers of the Ortin Global?

Ortin Global's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Adline Chem Lab, Ganga Pharma, Fabino Enter, and Brawn Biotech. While Sun Pharma and others show excellent management, growth, and capital structure, Ortin Global and its peers generally exhibit below-average performance in these areas.

Peers: The peers of Ortin Global are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Adline Chem Lab, Ganga Pharma., Fabino Enter, and Brawn Biotech.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Below Average management risk is found at Ortin Global, Ganga Pharma., Fabino Enter, and Brawn Biotech. Excellent growth is noted at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Ortin Global, Divi's Lab., Torrent Pharma, Ganga Pharma., Fabino Enter, and Brawn Biotech. Excellent capital structure is present at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Below Average capital structure is noted at Ortin Global, Ganga Pharma., Fabino Enter, and Brawn Biotech.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Ganga Pharma. has the lowest at -46.01%, with Ortin Global's 1-year return at -36.55% being significantly lower than Divi's Lab. and higher than Ganga Pharma. Additionally, the six-month returns for Adline Chem Lab, Ortin Global, Ganga Pharma., Fabino Enter, and Brawn Biotech are negative.

Is Ortin Global overvalued or undervalued?

As of November 15, 2023, Ortin Global is considered overvalued and risky, with a PE ratio of -9.19 and a year-to-date return of -39.33%, significantly underperforming compared to peers like Sun Pharma and Cipla, and the Sensex.

As of 15 November 2023, Ortin Global's valuation grade has moved from expensive to risky, indicating a significant shift in its market perception. The company is currently assessed as overvalued. Key ratios highlight its precarious financial position, with a PE ratio of -9.19, an EV to EBIT of -8.94, and a ROCE of -316.50%. These figures suggest that the company is struggling to generate positive returns on its capital.<BR><BR>In comparison to its peers, Ortin Global's valuation stands out unfavorably. For instance, Sun Pharma has a PE ratio of 35.25, while Cipla boasts a more attractive PE of 22.99, underscoring Ortin's relative weakness in the market. Additionally, Ortin's stock has underperformed significantly against the Sensex, with a year-to-date return of -39.33% compared to the Sensex's gain of 5.63%. This further reinforces the notion that Ortin Global is not only overvalued but also facing substantial challenges in its operational performance.

What is the technical trend for Ortin Global?

As of May 13, 2025, Ortin Global's technical trend is mildly bearish, influenced by mixed signals from MACD and moving averages, alongside bearish indicators from Bollinger Bands and Dow Theory.

As of 13 May 2025, the technical trend for Ortin Global has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The weekly RSI is bullish, but the monthly RSI shows no signal. Bollinger Bands are mildly bearish on both weekly and monthly time frames. Daily moving averages are also mildly bearish. The KST shows a mildly bullish trend weekly but is bearish monthly. Dow Theory indicates a mildly bearish stance weekly with no trend monthly. Overall, the current technical stance is mildly bearish, driven primarily by the mixed signals from MACD and moving averages, alongside the bearish indicators from Bollinger Bands and Dow Theory.

Who are the top shareholders of the Ortin Global?

The top shareholders of Ortin Global include Rajesh Poddar with 4.69% and promoter Sanka Tandav Krishna with 0.5%. Individual investors hold 85.32% of shares, while foreign institutional investors own 6.53%, with no pledged promoter holdings or mutual funds involved.

The top shareholders of Ortin Global include a mix of individual investors and institutional holdings. The largest individual shareholder is Rajesh Poddar, who holds 4.69% of the shares. Additionally, Sanka Tandav Krishna is the promoter with the highest holding at 0.5%. The company also has 85.32% of its shares held by individual investors. On the institutional side, 2 foreign institutional investors (FIIs) hold a combined total of 6.53%. There are no pledged promoter holdings or mutual funds involved in the shareholding.

How big is Ortin Global?

As of 24th July, Ortin Global Ltd has a market capitalization of 9.00 Cr and reported net sales of 49.03 Cr with a net loss of 0.28 Cr over the latest three quarters. Shareholder's funds are valued at 2.82 Cr, and total assets amount to 6.59 Cr as of March 2024.

As of 24th July, <BR><BR>Market Cap: Ortin Global Ltd has a market capitalization of 9.00 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest three quarters is 49.03 Cr. The sum of Net Profit for the latest three quarters shows a loss of 0.28 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2024. Shareholder's Funds are valued at 2.82 Cr, and Total Assets amount to 6.59 Cr.

Are Ortin Global latest results good or bad?

Ortin Laboratories' latest results are concerning, showing a flat performance with a Profit After Tax decline of 600% year-over-year, leading analysts to recommend a "Sell." Despite the company's commitment to growth, the financial challenges raise caution for investors.

Ortin Laboratories' latest financial results indicate a challenging situation for the company. For the quarter ending June 2024, the performance was flat, with a score of -3, which is an improvement from the previous quarter's score of -9. However, the Profit After Tax (PAT) has significantly decreased to -0.10 crore, marking a troubling 600% decline compared to the same quarter last year. This decline raises concerns about the company's profitability in the near term.<BR><BR>While Ortin Labs is committed to its mission of providing affordable and high-quality pharmaceutical products and is focused on expanding its product portfolio, the current financial performance has led to a "Sell" recommendation from analysts. This suggests that investors should approach their investment decisions with caution.<BR><BR>Overall, the latest results may not be viewed positively, as the company faces considerable challenges despite its commitment to growth and improvement.

How has been the historical performance of Ortin Global?

Ortin Global has experienced significant financial decline, with net sales dropping from 197.39 Cr in Mar'20 to 0.34 Cr in Mar'25, resulting in increasing losses and a negative operating profit. Total assets and liabilities have also decreased sharply, reflecting a deteriorating financial position.

Answer:<BR>The historical performance of Ortin Global has shown significant volatility over the years, particularly in net sales and profitability.<BR><BR>Breakdown:<BR>Ortin Global's net sales have dramatically decreased from 197.39 Cr in Mar'20 to just 0.34 Cr in Mar'25, reflecting a consistent decline over the years. Other operating income has remained minimal, contributing to total operating income dropping from 197.39 Cr in Mar'20 to 0.38 Cr in Mar'25. The company's total expenditure, excluding depreciation, peaked at 191.69 Cr in Mar'20 but has since fallen to 1.23 Cr in Mar'25, indicating a sharp reduction in operational costs. Despite this, the operating profit (PBDIT) has turned negative, from a profit of 5.89 Cr in Mar'20 to a loss of 0.85 Cr in Mar'25. Profit before tax and profit after tax have also shown a downward trend, with losses increasing from -0.56 Cr in Mar'20 to -0.85 Cr in Mar'25. The company's total assets have decreased from 116.52 Cr in Mar'20 to 3.72 Cr in Mar'25, while total liabilities have similarly declined from 116.52 Cr to 3.72 Cr over the same period. Cash flow from operating activities has been negative since Mar'24, with net cash inflow/outflow remaining at zero in Mar'25. Overall, Ortin Global's financial performance has deteriorated significantly, marked by declining revenues, increasing losses, and a shrinking asset base.

When is the next results date for Ortin Global Ltd?

The next results date for Ortin Global Ltd is 14 February 2026.

The next results date for Ortin Global Ltd is scheduled for 14 February 2026.

Why is Ortin Global Ltd falling/rising?

As of 08-Feb, Ortin Global Ltd's stock price is rising to 12.79, reflecting a 4.84% increase. This short-term recovery follows consecutive gains, although the stock has faced significant declines over the past month and year, indicating potential volatility ahead.

As of 08-Feb, Ortin Global Ltd's stock price is rising, currently at 12.79, reflecting a change of 0.59 (4.84%) upward. This increase can be attributed to several factors. Notably, the stock has outperformed its sector by 5.64% today and has experienced consecutive gains over the last two days, accumulating a total return of 10.07% in this period. <BR><BR>Despite a challenging longer-term performance, where the stock has declined by 11.12% over the past month and 23.91% over the past year, the recent upward movement indicates a short-term recovery. Additionally, the stock's current price is higher than both the 5-day and 200-day moving averages, suggesting a positive trend in the immediate term. However, it is important to note that there has been a significant drop in investor participation, with delivery volume on 05 Feb falling by 94.27% compared to the 5-day average, which could indicate potential volatility in future trading. <BR><BR>Overall, the recent gains in Ortin Global Ltd's stock price are primarily driven by short-term performance improvements, despite the broader context of declining returns over longer periods.

Which are the latest news on Ortin Global?